Soligenix, Inc. announced on July 9 that it has received notice of allowance for European and Canadian patent applications further extending protection around ThermoVax® including coverage of the Company’s ricin toxin vaccine, [Read more]
The Federal Bureau of Investigation (FBI) is seeking suppliers for anti-viral therapeutic Tamiflu to support is Pandemic Flu Preparedness Program stockpile. The FBI needs approximately 3,300 does of Tamiflu each year and [Read more]
By Jacqueline K. Olive, Peter J. Hotez, Ashish Damania, Melissa S. Nolan Summary Points A social movement of public health vaccine opposition has been growing in the United States in recent years; [Read more]
Characterized by the World Health Organization as a “neglected tropical disease,” leprosy (also known as Hansen’s disease) is caused by Mycobacterium leprae. Nearly a quarter of a million people are diagnosed with [Read more]
Enrollment has begun in an early-stage clinical trial testing the safety of two human monoclonal antibodies (mAbs) designed to treat people infected with Middle East respiratory syndrome coronavirus (MERS-CoV). The first reported [Read more]
The Experimental Therapeutics (ET) Branch of the Walter Reed Army Institute of Research (WRAIR) focuses on the development of new drugs to prevent and treat malaria, leishmaniosis, antibiotic-resistant bacteria, and other infectious [Read more]
Humanetics Corporation has been awarded a three-year contract valued at approximately $5.4 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The contract [Read more]
AntoXa Corporation has obtained a license from Defence Research & Development Canada (DRDC), an Agency of the Canadian Department of National Defence, to develop and produce an anti-ricin monoclonal antibody for sale [Read more]
The Biomedical Advanced Research and Development Authority (BARDA), Division of Research, Innovation and Ventures (DRIVe) is seeking applicants interested in working with BARDA DRIVe as part of a network of accelerators across [Read more]
The U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) will purchase an anthrax treatment for $25.2 million from Elusys Therapeutics Inc. of [Read more]
© 2018 STEMAR MEDIA